HSCS

Heart Test Laboratories, Inc. (HSCS) - 10-Q Summary

Business Context and Reporting Period

Company: Heart Test Laboratories, Inc. (d/b/a HeartSciences)
Reporting Period: Quarter ended July 31, 2024 (Fiscal Q1 2025)
Business Overview: A medical technology company developing AI-based electrocardiograph (ECG) solutions, specifically the MyoVista wav ECG device and the MyoVista Insights Cloud Platform. The company is pre-revenue in the U.S. pending FDA clearance, which is targeted for submission in Q1 2025.
Corporate Action: A 1-for-100 reverse stock split was effected on May 17, 2024, to regain compliance with Nasdaq listing requirements.

Key Financial Metrics

Note: Revenue is $0 as the company has not yet received FDA clearance to sell its primary device in the U.S. Market.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased 56% to $2.08 million from $1.33 million.
  • R&D Expenses: Increased 117% to $1.22 million, driven by consulting costs for the Cloud Platform and increased headcount for FDA submission preparation.
  • SG&A Expenses: Increased 11% to $0.85 million, primarily due to payroll and professional fees related to the reverse stock split.
• Net Loss: Increased 50% to $2.05 million due to higher operating costs, partially offset by a reduction in interest expense (down 36%) following the conversion of certain notes to equity in the prior year.
• Liquidity: Cash balance decreased by $1.47 million during the quarter due to operating burn, despite raising approximately $0.6 million in financing activities (stock sales).
• Debt Structure: The $500,000 FRV Note was reclassified from current to long-term liability following an extension of its maturity date to September 30, 2025.

Outlook, Risks, and Contingencies

• Going Concern: Management has raised substantial doubt regarding the company's ability to continue as a going concern. Current cash resources are deemed insufficient to fund operations for the next 12 months without additional financing.
• Regulatory Path: The company is preparing a 510(k) submission for the MyoVista wav ECG device, targeting Q1 2025. Success is critical for U.S. commercialization.
• Recent Financing (Subsequent Event): In September 2024, the company entered into a Note Purchase Agreement with Streeterville Capital, LLC for a $2.51 million unsecured promissory note (net proceeds ~$1.9 million). The note bears 8.5% interest and matures in 18 months.
• Capital Resources: The company maintains an Equity Line with Lincoln Park Capital ($15M capacity) and an At-The-Market (ATM) facility with Maxim Group ($15M capacity). Proceeds from these facilities are used for working capital.
• Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, citing lack of proper approval processes, insufficient accounting resources, and inadequate segregation of duties.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $4.3M cash balance plus the $1.9M Streeterville note proceeds against the projected burn rate to fund the FDA submission and subsequent launch.
• FDA Timeline: Confirm the Q1 2025 submission target for the 510(k) clearance and the potential for delays.
• Dilution Risk: Monitor the utilization of the Equity Line and ATM facility, as well as the conversion terms of the new Streeterville note, which may lead to significant equity dilution.
• Debt Covenants: Review the terms of the Streeterville note, specifically the redemption rights and the 5% balance increase penalty if the principal is not reduced by $900,000 within 12 months.
• Internal Controls: Assess the progress of remediation efforts regarding the disclosed material weaknesses in financial reporting.